Electromed, Inc.

Electromed, Inc. operates in the medical device industry, specifically developing, manufacturing, and selling products that provide High Frequency Chest Wall Oscillation (HFCWO) therapy for patients with compromised pulmonary function ¹. The U.S. homecare market for HFCWO is estimated to be growing at a compound annual growth rate of approximately 8% ², with bronchiectasis representing the fastest growing diagnostic category, growing at 12% annually ³. The company estimates that there are approximately one million Americans diagnosed with bronchiectasis, with a 16% penetration of HFCWO within that population ⁴. The market is expanding due to an aging population, higher incidence of chronic lung disease, growing physician awareness, and treatments moving to lower cost homecare settings ⁵.

Electromed faces competition from Baxter International Inc., which was the only manufacturer of an HFCWO product cleared by the FDA until Electromed introduced its original MedPulse Respiratory Vest System in 2000 ⁶. Philips, which received FDA clearance for its inCourage Airway Clearance Therapy in 2005, and Tactile Medical, which sells the AffloVest primarily through HME companies, also compete in the same market ⁷. The company believes it distinguishes itself through competitive advantages in patient comfort, ease of use, and effectiveness of HFCWO treatment ⁸. Electromed's direct sales force and dedication to advancing education on HFCWO awareness positions it to drive market awareness and growth ⁹.

Electromed primarily employs a direct-to-patient and provider model, obtaining patient referrals from clinicians, managing insurance claims on behalf of patients, and delivering the SmartVest System directly to patients with training in their homes ¹⁰. This model disintermediates the traditional home medical equipment channel, allowing the company to capture both manufacturer and distributor margins ¹¹. The company also sells products in the acute care setting for patients in post-surgical or intensive care units, or those admitted for lung infections ¹². Revenue is generated from homecare sales, hospital sales, homecare distributor sales, and other revenue, with most revenue coming from domestic homecare sales through a physician referral model ¹³.

The SmartVest System, the company's primary product, is available in two models: SmartVest SQL and SmartVest Clearway ¹⁴. The SmartVest Clearway, introduced in November 2022, is the next generation HFCWO system designed around an enhanced patient experience and modern design ¹⁵. It features 360-degree oscillation coverage, patented Soft Start technology, an open system design with Breathing Room, a programmable generator with an intuitive touchscreen, a patented single-hose design, and a lightweight generator weighing less than 14 pounds ¹⁶. The company also markets the Single Patient Use SmartVest and SmartVest Wrap to health care providers in the acute care setting ¹⁷.

In fiscal 2026, Electromed averaged 58 direct field sales employees ¹⁸ and had a network of approximately 167 respiratory therapists across the U.S. to assist with in-home patient training ¹⁹. The company's reimbursement department works on behalf of patients to seek insurance authorization and process claims ²⁰. As of June 30, 2026, Electromed estimated it had over 275 million, or 87%, contracted lives in the U.S. ²¹. The company also sells products outside the U.S. primarily through independent distributors, with principal distributors located in the Middle East, Southeast Asia, and Central America ²².

During fiscal 2026, Electromed announced a stock repurchase authorization on September 9, 2025, allowing the repurchase of up to $10.0 million of outstanding shares ²³. As of June 30, 2026, a total of 151,911 shares had been repurchased under the authorization with an average cost of $25.79 per share ²⁴. The company also entered into a new credit agreement in December 2025, providing a senior secured credit facility with a $10,000,000 revolving line of credit ²⁵. Electromed continues to invest in clinical evidence, including a 2025 retrospective analysis of the Bronchiectasis and Nontuberculous Mycobacteria Research Registry ²⁶.

Electromed's total revenue increased to $73,776,000 in fiscal 2026, up 15.3% from $64,000,000 in fiscal 2025 ²⁷. Net income increased to $11,301,000 in fiscal 2026, up 49.9% from $7,537,000 in fiscal 2025 ²⁸. Gross profit increased to $57,943,000, or 78.5% of net revenues, from $49,971,000, or 78.1% of net revenues, in fiscal 2025 ²⁹. Operating income increased by 43.7% to $13,881,000 in fiscal 2026 from $9,660,000 in fiscal 2025 ³⁰.

Electromed's key growth strategies for fiscal 2027 are to accelerate revenue growth by taking market share and expanding the addressable population for the largest and fastest growing segments of the market: adult pulmonology and bronchiectasis ³¹. Actions to support this include expanding the sales force in geographies with high potential, increasing SmartVest brand awareness through direct-to-consumer and physician marketing, providing best-in-class customer care and support, and developing and promulgating the body of bronchiectasis clinical evidence to increase physician adoption ³².

The company expects to achieve future sales, earnings, and overall market share growth through sales force expansion, a continued focus on product innovation, improved patient experience and clinical outcomes in the homecare market ³³. Electromed continues to evaluate opportunities to offer the SmartVest System through selected HME distributors, while expecting to continue its direct sales channel as the primary homecare revenue source ³⁴. The company also plans to support its current international distributors with less emphasis on contracting with new distributors ³⁵.

Electromed expects that component and raw material costs will continue to be a challenge in fiscal 2027 due to supply chain constraints, rising energy costs from ongoing geopolitical conflict, uncertainty related to trade regulations such as tariffs, and inflationary trends in electronic components ³⁶. The company has purchased key materials in advance in certain instances to ensure adequate future supply and mitigate the risk of potential supply chain disruptions ³⁷. Any significant increases to raw material or shipping costs would reduce gross margins ³⁸.

Electromed's manufacturing facility in New Prague, Minnesota includes more than 14,000 square feet of dedicated manufacturing and engineering space ³⁹. The company is certified on an annual basis to be compliant with ISO 13485 quality system standards ⁴⁰. Many of its strategic suppliers are located within 100 miles of its headquarters, enabling close monitoring of the component supply chain ⁴¹. The company maintains established inventory levels for critical components and finished goods to assure continuity of supply ⁴².

In fiscal 2026, Electromed incurred R&D expenses of approximately $1,314,000, or 1.8% of net revenues ⁴³. The company spent approximately $1,252,000 on property and equipment during fiscal 2026 ⁴⁴. Electromed has a stock repurchase authorization allowing the repurchase of up to $10.0 million of outstanding shares, with approximately $6,082,000 remaining available as of June 30, 2026 ⁴⁵. The company has never paid cash dividends and currently intends to retain any earnings for use in operations, not anticipating paying cash dividends in the foreseeable future ⁴⁶.

Electromed faces potential headwinds from the One Big Beautiful Bill Act, signed into law on July 4, 2025, which contains budgetary cuts and increased regulatory requirements to Medicaid, Medicare, the ACA, and other federal programs ⁴⁷. The legislation is predicted to increase the number of uninsured by 11.8 million by 2034, relative to current law ⁴⁸. The company could also be adversely affected by the Loper Bright decision, which modified the regulatory interpretation standard and is expected to result in a chill in future federal rulemaking and a significant increase in litigation challenging existing and future federal rules and regulations ⁴⁹.

Electromed's sales continue to be dependent, in part, on the availability of coverage and reimbursement from third-party payers ⁵⁰. The Medicare total allowable amount of reimbursement for HCPCS code E0483 is approximately $16,000, while state Medicaid programs range from approximately $8,000 to $15,000 ⁵¹. Actual reimbursement from third-party payers can vary and can be significantly less than the full allowable amount ⁵².

Electromed's business is heavily dependent on reimbursement from third-party payers, including Medicare, Medicaid, and private insurers, and any reduction in federal health care program spending or changes to reimbursement policies could substantially reduce revenues ⁵³. The company faces intense competition from established players like Baxter and Philips, as well as new entrants and alternative therapies, including pharmaceutical treatments for bronchiectasis ⁵⁴. Supply chain disruptions, component shortages, and inflationary trends in electronic components could increase costs and reduce gross margins ⁵⁵. The company's international sales are subject to adverse international health care regulation, and its domestic sales depend on maintaining regulatory compliance and gaining future regulatory approvals ⁵⁶. Additionally, the company's credit facility matures on December 16, 2026, and if not renewed, could impact liquidity ⁵⁷.

Management's message emphasizes the goal of making HFCWO treatments as effective, convenient, and comfortable as possible so patients can breathe easier and live better with improved respiratory function and fewer exacerbations ⁵⁸. The company is driven to make life's important moments possible, one breath at a time, by continually investing in clinical evidence that supports the therapeutic imperative of clearing excess mucus from the lungs ⁵⁹. Management's key growth strategies for fiscal 2027 focus on accelerating revenue growth by taking market share and expanding the addressable population for the largest and fastest growing segments of the market: adult pulmonology and bronchiectasis ⁶⁰. The company plans to expand its sales force in geographies with high potential, increase SmartVest brand awareness through direct-to-consumer and physician marketing, provide best-in-class customer care and support, and develop and promulgate the body of bronchiectasis clinical evidence to increase physician adoption ⁶¹. Management believes that generating additional clinical evidence to further support the SmartVest System as a preferred treatment for bronchiectasis patients will remain a focus in fiscal 2027 ⁶².